Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Polyvalent complexes for vaccine development.

Wang L, Huang P, Fang H, Xia M, Zhong W, McNeal MM, Jiang X, Tan M.

Biomaterials. 2013 Jun;34(18):4480-92. doi: 10.1016/j.biomaterials.2013.02.041. Epub 2013 Mar 15.

2.

Branched-linear and agglomerate protein polymers as vaccine platforms.

Wang L, Xia M, Huang P, Fang H, Cao D, Meng XJ, McNeal M, Jiang X, Tan M.

Biomaterials. 2014 Sep;35(29):8427-38. doi: 10.1016/j.biomaterials.2014.06.021. Epub 2014 Jun 28.

3.

A dual vaccine candidate against norovirus and hepatitis E virus.

Wang L, Cao D, Wei C, Meng XJ, Jiang X, Tan M.

Vaccine. 2014 Jan 16;32(4):445-52. doi: 10.1016/j.vaccine.2013.11.064. Epub 2013 Nov 27.

4.

Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice.

Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V.

PLoS One. 2013 Jul 26;8(7):e70409. doi: 10.1371/journal.pone.0070409. Print 2013.

5.

A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus.

Xia M, Wei C, Wang L, Cao D, Meng XJ, Jiang X, Tan M.

Vaccine. 2016 Feb 10;34(7):905-13. doi: 10.1016/j.vaccine.2015.12.068. Epub 2016 Jan 9.

6.

A candidate dual vaccine against influenza and noroviruses.

Xia M, Tan M, Wei C, Zhong W, Wang L, McNeal M, Jiang X.

Vaccine. 2011 Oct 13;29(44):7670-7. doi: 10.1016/j.vaccine.2011.07.139. Epub 2011 Aug 11.

7.

A dual chicken IgY against rotavirus and norovirus.

Dai YC, Zhang XF, Tan M, Huang P, Lei W, Fang H, Zhong W, Jiang X.

Antiviral Res. 2013 Mar;97(3):293-300. doi: 10.1016/j.antiviral.2012.12.011. Epub 2012 Dec 22.

8.

Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis.

Blazevic V, Lappalainen S, Nurminen K, Huhti L, Vesikari T.

Vaccine. 2011 Oct 19;29(45):8126-33. doi: 10.1016/j.vaccine.2011.08.026. Epub 2011 Aug 18.

PMID:
21854823
9.

Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector.

Ma Y, Duan Y, Wei Y, Liang X, Niewiesk S, Oglesbee M, Li J.

J Virol. 2014 May;88(9):5122-37. doi: 10.1128/JVI.00019-14. Epub 2014 Feb 26.

10.

Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.

Tan M, Jiang X.

Nanomedicine (Lond). 2012 Jun;7(6):889-97. doi: 10.2217/nnm.12.62. Review.

12.

Immunological response to recombinant VP8* subunit protein of bovine roravirus in pregnant cattle.

Lee J, Babiuk LA, Harland R, Gibbons E, Elazhary Y, Yoo D.

J Gen Virol. 1995 Oct;76 ( Pt 10):2477-83.

PMID:
7595351
13.

Norovirus P particle, a novel platform for vaccine development and antibody production.

Tan M, Huang P, Xia M, Fang PA, Zhong W, McNeal M, Wei C, Jiang W, Jiang X.

J Virol. 2011 Jan;85(2):753-64. doi: 10.1128/JVI.01835-10. Epub 2010 Nov 10.

15.

Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines.

Giles BM, Bissel SJ, Dealmeida DR, Wiley CA, Ross TM.

Clin Vaccine Immunol. 2012 Feb;19(2):128-39. doi: 10.1128/CVI.05533-11. Epub 2011 Dec 21.

16.
17.

Targeting of non-dominant antigens as a vaccine strategy to broaden T-cell responses during chronic viral infection.

Holst PJ, Jensen BA, Ragonnaud E, Thomsen AR, Christensen JP.

PLoS One. 2015 Feb 13;10(2):e0117242. doi: 10.1371/journal.pone.0117242. eCollection 2015.

18.

Heat shock protein 110 improves the antitumor effects of the cytotoxic T lymphocyte epitope E7(49-57) in mice.

Ren F, Xu Y, Mao L, Ou R, Ding Z, Zhang X, Tang J, Li B, Jia Z, Tian Z, Ni B, Wu Y.

Cancer Biol Ther. 2010 Jan;9(2):134-41. Epub 2010 Jan 21.

PMID:
19901562
19.

An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.

Khalil SM, Tonkin DR, Snead AT, Parks GD, Johnston RE, White LJ.

J Virol. 2014 Aug;88(16):9182-96. doi: 10.1128/JVI.00327-14. Epub 2014 Jun 4.

20.

Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.

Kocher J, Bui T, Giri-Rachman E, Wen K, Li G, Yang X, Liu F, Tan M, Xia M, Zhong W, Jiang X, Yuan L.

J Virol. 2014 Sep 1;88(17):9728-43. doi: 10.1128/JVI.01249-14. Epub 2014 Jun 11.

Supplemental Content

Support Center